Skip to main content

Table 2 Proteins differentiating between microalbuminuric and non-microalbuminuric groups

From: Early urinary biomarkers of diabetic nephropathy in type 1 diabetes mellitus show involvement of kallikrein-kinin system

    

Theoreticala

MS

MS/MS

  

Spot No

Protein Name

SwissProt entry

Biological functionb

MW (kDa)

pI

Peptide count

Protein score

Peptide count

Total ion score

Spot intensity ratioc

pd

1

Kininogen-1

KNG1

blood coagulation, source of bradykinin

71912

6,34

  

5

184

0.110

<0,0001

2

Alpha-enolase

ENOA

glycolysis (step 9/10), cell growth, fibrinolysis

47139

7,01

  

4

106

0.076

<0,0001

3

Glyceraldehyde-3-phosphate dehydrogenase

G3P

glycolysis (step 6/10), nuclear regulatory functions, apoptosis

36030

8,57

  

2

57

0.018

<0,0001

4

Alpha-enolase

ENOA

 

47139

7,01

6

57

5

257

0.140

<0,0001

5

Glyceraldehyde-3-phosphate dehydrogenase

G3P

 

36030

8,57

  

1

70

0.091

<0,0001

6

Vesicular integral-membrane protein VIP36

LMAN2

intracellular protein trafficking (Golgi to ER)

40203

6,46

  

2

81

0.335

<0,001

7

Protein AMBP

AMBP

trypsin inhibitor

38974

5,95

  

1

35

0.331

<0,01

8

Fibrinogen alpha chain

FIBA

blood coagulation

94914

5,7

  

2

40

0.238

<0,001

9

Glutaminyl-peptide cyclotransferase

QPCT

N-terminal pyroglutamate formation

40851

6,12

8

67

4

161

0.165

<0,001

10

Glutaminyl-peptide cyclotransferase

QPCT

 

40851

6,12

  

3

99

0.190

<0,0001

11

Basement membrane-specific heparan sulphate proteoglycan core protein

PGBM

component of basement membrane, anti-angiogenesis

468501

6,06

  

5

347

0. 364

<0,001

12

Non-secretory ribonuclease

RNAS2

non-secretory ribonuclease

18342

9,1

  

5

391

0.162

<0,001

13

Multimerin-2

MMRN2

endothelial surface protein, anti-angiogenesis

104344

5,56

  

1

51

0.202

<0,01

14

Peptidoglycan recognition protein 1

PGRP1

pattern recognition, innate immunity

21717

8,92

  

2

122

0.366

<0,01

14

Phosphatidylethanolamine-binding protein 1

PEBP1

serine protease inhibitor, Raf kinase inhibitor

21044

7,01

  

1

58

<0,01

15

Inter-alpha-trypsin inhibitor heavy chain H4

ITIH4

immunomodulation (acute phase)

103293

6,51

  

2

46

0.406

<0,01

16

Secreted and transmembrane protein 1

SCTM1

T-cell co-stimulatory ligand

27022

7

  

2

93

0.219

<0,01

17

Secreted and transmembrane protein 1

SCTM1

 

27022

7

  

1

37

0.156

<0,001

18

Serum albumin

ALBU

major plasma protein

69321

5,92

  

2

82

1.9

<0,001

19

Serum albumin

ALBU

 

69321

5,92

  

2

63

4.4

<0,01

20

Ig lambda-2 chain C region

LAC2

immunoglobulin

11287

6.92

  

2

188

3.1

<0,0001

20

Ig kappa chain C region

IGKC

immunoglobulin

11602

5.58

  

1

44

<0,05

21

Zinc-alpha-2-glycoprotein

ZA2G

fatty acid binding

34237

5,71

10

54

2

196

3.8

<0,0001

22

Serotransferrin

TRFE

iron binding, cell proliferation

77000

6,81

23

119

3

193

2.8

<0,01

23

Ceruloplasmin

CERU

copper binding

122128

5,44

  

7

495

1.2

<0,0001

24

Serum albumin

ALBU

 

69321

5,92

  

4

150

3.9

<0,001

25

Serum albumin

ALBU

 

69321

5,92

  

2

83

3.9

<0,01

26

Serum albumin

ALBU

 

69321

5,92

  

2

113

5.0

<0.01

27

Mannan-binding lectin serine protease 2

MASP2

complement activation (lectin pathway)

75685

5,47

  

7

430

4.2

<0,001

28

Serum albumin

ALBU

 

69321

5,92

  

4

95

5.6

<0,0001

29

Serum albumin

ALBU

 

69321

5,92

  

2

46

8.5

<0,0001

30

Alpha-1-acid glycoprotein 1

A1AG1

immunomodulation (acute phase)

23497

4,93

  

2

82

4.1

<0,001

31

Serotransferrin

TRFE

 

77000

6,81

22

111

4

248

11.6

<0,0001

32

Serotransferrin

TRFE

 

77000

6,81

23

147

8

268

3.8

<0,0001

33

Serotransferrin

TRFE

 

77000

6,81

26

151

5

396

5.5

NS

  1. aTheoretical MW and pI were retrieved from SwissProt database and correspond to intact proteins, irrespective of post-translational modifications
  2. bDescriptions of proteins’ biological functions were extracted from SwissProt database
  3. cSpot intensity ratios are calculated from group averages and expressed relative to non-microalbuminuric group
  4. dMedian spot volumes were compared between the two groups using Mann–Whitney rank sum test
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us